SCHEMBL10116468

SCHEMBL10116468

CC(C)S(=O)(=O)Nc1ccc(C(=O)Nc2ccc(Cl)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
MEN1 O00255 2/20 0.60
LMNA P02545 2/20 0.59
KDM4E B2RXH2 1/20 0.59
MAPT P10636 2/20 0.58
HSD17B10 Q99714 1/20 0.58
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
PRMT1 Q99873 1/20 0.55
HTT P42858 1/20 0.54
NT5E P21589 1/20 0.53
MAPK1 P28482 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA9 Q16790 1/20 0.52
ENPP3 O14638 4/20 0.51
ENPP1 P22413 4/20 0.51
ENPP2 Q13822 1/20 0.51
NAMPT P43490 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116464 0.88 LMNA (0.76) LMNAKDM4EMAPTNPC1RAB9A
SCHEMBL10116526 0.87 KDM4E (0.74) KMT2AMEN1LMNAKDM4EMAPT
SCHEMBL10116460 0.87 NPC1 (0.67) KMT2AMEN1LMNAKDM4EMAPT
SCHEMBL10116458 0.87 GRIA4 (0.60) KMT2AMEN1LMNAKDM4EMAPT
SCHEMBL10116634 0.85 MEN1 (0.61) KMT2AMEN1LMNAKDM4ENPC1
SCHEMBL10116627 0.85 LMNA (0.56) KMT2AMEN1LMNAKDM4EMAPT
SCHEMBL10802804 0.85 KDM4E (0.56) KMT2AMEN1LMNAKDM4EMAPT
SCHEMBL10116503 0.85 ADORA3 (0.64) KMT2AMEN1LMNAKDM4EMAPT
SCHEMBL2562502 0.85 GRIA4 (0.65) KMT2AMEN1LMNAKDM4EMAPT
SCHEMBL10116494 0.85 NPC1 (0.61) KMT2AMEN1LMNAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R KMT2A 2912/4885MEN1 2876/4885LMNA 1925/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R KMT2A 2768/4885MEN1 2932/4885LMNA 2068/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R KMT2A 2953/4885MEN1 2926/4885LMNA 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.